Back to All Resources

IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints in Murine Models of IL-33/36- as well as Th17-driven Inflammation

May 10, 2021

American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting

poster-thumbnail
View Poster
Area of Focus
Immunology
Programs
IRAK4 (KT-474)
Indications
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
View Resource